| Literature DB >> 33731876 |
Katherine Crawford1,2, Julie Xian1,3,4,5, Katherine L Helbig1,3,4, Peter D Galer1,3,4, Shridhar Parthasarathy1,3,4,6, David Lewis-Smith7,8, Michael C Kaufman1,3,4, Eryn Fitch1,3, Shiva Ganesan1,3,4, Margaret O'Brien1,3, Veronica Codoni9, Colin A Ellis3,4,10, Laura J Conway2, Deanne Taylor4,11, Roland Krause9, Ingo Helbig12,13,14,15.
Abstract
PURPOSE: Pathogenic variants in SCN2A cause a wide range of neurodevelopmental phenotypes. Reports of genotype-phenotype correlations are often anecdotal, and the available phenotypic data have not been systematically analyzed.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33731876 PMCID: PMC8257493 DOI: 10.1038/s41436-021-01120-1
Source DB: PubMed Journal: Genet Med ISSN: 1098-3600 Impact factor: 8.822
Recurrent variants identified in the cohort.
| Recurrent variants | Broad phenotype (individuals) | Variant class | Location | |
|---|---|---|---|---|
| p.R853Q | 18 | DEE (16) ASD (2) | Missense | Helical repeat II |
| p.A263V | 14 | DEE (8) BFNIS (5) ASD (1) | Missense | Helical repeat I |
| p.R1882Q | 10 | DEE (10) | Missense | Cytoplasmic |
| p.E999K | 8 | DEE (7) Other epilepsy (1) | Missense | Cytoplasmic |
| p.L1342P | 5 | DEE (5) | Missense | Helical repeat III |
| p.R1319Q | 5 | BFNIS (3) DEE (2) | Missense | Helical repeat III |
| p.L1650P | 4 | Atypical (3) DEE (1) | Missense | Cytoplasmic |
| p.M1545V | 4 | DEE (3) Other epilepsy (1) | Missense | Helical repeat IV |
| p.R1629H | 4 | DEE (3) BFNIS (1) | Missense | Helical repeat IV |
| p.V261M | 4 | DEE (2) BFNIS (2) | Missense | Helical repeat I |
| p.E1211K | 3 | DEE (3) | Missense | Helical repeat III |
| p.E1321K | 3 | BFNIS (2) ASD (1) | Missense | Cytoplasmic |
| p.M136I | 3 | DEE (3) | Missense | Helical repeat I |
| p.R102* | 3 | DEE (2) Atypical (1) | Nonsense | Cytoplasmic |
| p.R1319L | 3 | DEE (2) Other epilepsy (1) | Missense | Helical repeat III |
| p.R1435* | 3 | ASD (2) DEE (1) | Nonsense | Extracellular |
| p.R36G | 3 | BFNIS (2) Other epilepsy (1) | Missense | Cytoplasmic |
| p.R856Q | 3 | DEE (3) | Missense | Helical repeat II |
| p.R937C | 3 | ASD (2) Atypical (1) | Missense | Pore-forming |
| p.S1336Y | 3 | DEE (3) | Missense | Cytoplasmic |
| p.S987I | 3 | DEE (1) BFNIS (1) Other epilepsy (1) | Missense | Cytoplasmic |
Variants identified three or more times in the sample with class and location. Broad phenotype refers to categories described in Supplementary Table 2.
ASD autism spectrum disorder, BFNIS benign familial neonatal–infantile seizures, DEE developmental and epileptic encephalopathies.
Fig. 1Overview of SCN2A variants and associated phenotypic features.
(a) The NaV1.2 channel (above) and gene (below), highlighting a selection of recurrent variants. (b) The frequency of phenotypic features within categorized phenotypic subgroups: developmental and epileptic encephalopathy (DEE, n = 255), autism (ASD, n = 60), benign familial neonatal–infantile seizures (BFNIS, n = 53), Other epilepsy (n = 27), and atypical SCN2A-related phenotypes (n = 18). Boxed frequencies indicate the five most frequent Human Phenotype Ontology (HPO) terms within each respective phenotypic subgroup. CNS central nervous system, EEG electroencephalogram, PTV protein-truncating variant.
Phenotypic terms associated with PTV and missense variants (n = 409).
| HPO term | HPO code | Odds ratio (95% CI) | Frequency | |
|---|---|---|---|---|
| Behavioral abnormality | HP:0000708 | 4.07×10-14 | 8.61 (4.57–17.01) | 0.76 |
| Autism | HP:0000717 | 1.06×10-13 | 8.16 (4.49–15.13) | 0.63 |
| Autistic behavior | HP:0000729 | 2.31×10-13 | 7.76 (4.26–14.50) | 0.68 |
| Stereotypy | HP:0000733 | 1.30×10-5 | 5.49 (2.45–12.22) | 0.24 |
| Sleep disturbance | HP:0002360 | 1.43×10-5 | 7.04 (2.76–18.32) | 0.19 |
| Childhood onset | HP:0011463 | 0.0004 | 3.57 (1.71–7.29) | 0.25 |
| Delayed speech and language development | HP:0000750 | 0.0005 | 3.72 (1.70–7.96) | 0.22 |
| Intellectual disability, moderate | HP:0002342 | 0.0013 | 3.83 (1.59–8.94) | 0.18 |
| Neurodevelopmental abnormality | HP:0012759 | 0.0023 | 2.58 (1.35–5.24) | 0.79 |
| Short attention span | HP:0000736 | 0.0047 | 3.83 (1.38–10.20) | 0.13 |
| Hyperactivity | HP:0000752 | 0.0047 | 3.83 (1.38–10.20) | 0.13 |
| Attention deficit–hyperactivity disorder | HP:0007018 | 0.0047 | 3.83 (1.38–10.20) | 0.13 |
| Involuntary movements | HP:0004305 | 0.01 | 2.65 (1.30–5.25) | 0.25 |
| Neonatal onset | HP:0003623 | 4.69×10-14 | Inf (11.88–Inf) | 0.40 |
| Seizures | HP:0001250 | 3.71×10-13 | 8.91 (4.77–16.83) | 0.89 |
| Epileptic spasms | HP:0011097 | 1.44×10-6 | Inf (4.39–Inf) | 0.20 |
| Infantile spasms | HP:0012469 | 2.62×10-6 | Inf (4.15–Inf) | 0.19 |
| Infantile onset | HP:0003593 | 3.77×10-6 | 11.44 (2.93–98.45) | 0.26 |
| Interictal epileptiform activity | HP:0011182 | 8.29×10-6 | 3.71 (1.97–7.38) | 0.51 |
| Focal-onset seizure | HP:0007359 | 1.61×10-5 | 4.08 (1.98–9.26) | 0.41 |
| Interictal EEG abnormality | HP:0025373 | 2.85×10-5 | 3.42 (1.83–6.68) | 0.51 |
| Abnormal nervous system electrophysiology | HP:0001311 | 6.00×10-5 | 3.09 (1.70–5.80) | 0.55 |
| EEG abnormality | HP:0002353 | 6.00×10-5 | 3.09 (1.70–5.80) | 0.55 |
| Abnormality of CNS electrophysiology | HP:0030178 | 6.00×10-5 | 3.09 (1.70–5.80) | 0.55 |
| Hypsarrhythmia | HP:0002521 | 0.0001 | Inf (2.88–Inf) | 0.14 |
| EEG with burst suppression | HP:0010851 | 0.0002 | 13.69 (2.27–558.40) | 0.17 |
| Generalized-onset seizure | HP:0002197 | 0.0005 | 2.77 (1.50–5.34) | 0.48 |
| EEG with focal epileptiform discharges | HP:0011185 | 0.0008 | 3.20 (1.50–7.61) | 0.33 |
| EEG with generalized epileptiform discharges | HP:0011198 | 0.0014 | 3.02 (1.46–6.88) | 0.34 |
| Multifocal epileptiform discharges | HP:0010841 | 0.0019 | 4.27 (1.51–16.70) | 0.21 |
| Encephalopathy | HP:0001298 | 0.0030 | 2.59 (1.31–5.53) | 0.36 |
| Generalized tonic seizures | HP:0010818 | 0.0030 | 4.20 (1.48–16.41) | 0.21 |
| Epileptic encephalopathy | HP:0200134 | 0.0065 | 2.50 (1.26–5.32) | 0.35 |
| Focal tonic seizures | HP:0011167 | 0.0077 | 5.39 (1.35–46.94) | 0.14 |
| Abnormality of the cerebrum | HP:0002060 | 0.01 | 2.84 (1.23–7.65) | 0.25 |
All significantly associated terms that remained significant after correction for multiple testing.
CI confidence interval, CNS central nervous system, EEG electroencephalogram, HPO Human Phenotype Ontology, PTV protein-truncating variants.
Fig. 2Recurrent variant phenograms.
(a) Phenogram comparing the frequency of Human Phenotype Ontology (HPO) terms in individuals with variant p.L1342P and the remainder of the cohort. (b) Phenogram comparing the frequency of HPO terms in individuals with variant p.A263V and the remainder of the cohort. (c) Phenogram comparing the frequency of HPO terms in individuals with variant p.R853Q and the remainder of the cohort. Red points indicate HPO terms with uncorrected p values <0.05, blue points indicate HPO terms with uncorrected p values ≥0.05. EEG electroencephalogram.
Fig. 3Logistic principal component analysis (PCA) and receiver-operating characteristic curves (ROC) allow for variant function prediction.
(a) ROC performance measurements (area under the curve [AUC]) for phenotypic subgroup comparisons between developmental and epileptic encephalopathy (DEE), benign familial neonatal–infantile seizures (BFNIS), and autism. A darker shade of blue indicates a higher performance for separating between phenotypic groups. (b) The second major principal component (PC2) separates individuals with known loss-of-function (LoF) (blue) and gain-of-function (GoF) (red) variants. (c) Density plot of PC2 across all individuals with known LoF (blue), GoF (red), and unmeasured variants (gray). (d) ROC for PC2 (yellow) shows higher performance for separating GoF from LoF variants. (e) Positive predictive values (PPV) for GoF and LoF variants with PC2 values for individuals with specific variants are highlighted on the graph. Some variants appear twice as phenotypes in individuals with recurrent variants may differ.